Sunday, July 13, 2025 – The provided text offers a comprehensive overview of how obesity has been understood and depicted across different historical periods, from ancient civilizations to the present day. It traces

Saturday, July 12, 2025 – This document presents a pilot feasibility study published in “Obesity Science & Practice” that investigates the effectiveness of an AI-driven Virtual Human (VH) intervention designed to enhance General Practitioner (GP)

Friday, July 11, 2025 – This scholarly article from Aesthetic Surgery Journal Open Forum discusses the phenomenon of “Ozempic Face,” a term used to describe the accelerated facial aging and volume loss experienced by some patients

Thursday, July 10, 2025 – There is growing evidence—especially in the plastic surgery community—that the recent surge in GLP‑1 medications (like Ozempic, Wegovy, Mounjaro) for weight loss is fueling a

Monday, July 7, 2025 – The provided text, originating from the Food and Drug Administration (FDA), serves as a crucial public health warning regarding counterfeit Ozempic (semaglutide) injections found within the U.S. drug

Saturday, July 5, 2025 – This original research article examines the real-world effectiveness of semaglutide and tirzepatide for obesity treatment, focusing on how medication discontinuation impacts weight loss and glycemic control. The retrospective cohort study analyzed electronic health records from

Monday, June 30, 2025 – We ask experts for their views on the GLP-1 market in this exclusive eBook. GLP-1 receptor agonists have rapidly evolved from niche diabetes drugs to

Monday, June 30, 2025 – Your Weight Matters Regional is traveling the country, bringing expert-led education and practical guidance to cities near you. These FREE half-day events are designed to

Tuesday, June 24, 2025 – This document details a Phase 3a, 68-week, multicenter, double-blind, placebo-controlled, and active-controlled clinical trial (REDEFINE 1) investigating the efficacy and safety of cagrilintide–semaglutide (CagriSema) for weight loss in adults

Tuesday, June 24, 2025 – https://my.clevelandclinic.org/health/treatments/13901-glp-1-agonists The provided text from the Cleveland Clinic offers a comprehensive overview of GLP-1 agonists, a class of medications primarily used to manage Type 2 diabetes and obesity. It explains how these

Sunday, June 22, 2025 – This scientific paper presents the ACHIEVE-1 trial, a phase 3 study investigating orforglipron, an oral, nonpeptide GLP-1 receptor agonist, for treating type 2 diabetes. The research evaluates its efficacy

Thursday, June 19, 2025 – 🧪 NA‑931 (Bioglutide™) – Biomed Industries, Inc.Presentation (Oral):Title: “Phase 2 Clinical Trials of NA‑931, an Oral Novel Quadruple IGF‑1, GLP‑1, GIP, and Glucagon Receptor Agonist,

Sunday, June 15, 2025 – Kommu S, Sharma PP, Gabor RM. Efficacy and Safety of Tirzepatide on Weight Loss in Patients Without Diabetes Mellitus: A Systematic Review and Meta-Analysis of

Monday, June 9, 2025 – Wikipedia is a free, multilingual, web-based, and openly editable encyclopedia maintained by a global community of volunteers. It’s hosted by the non-profit Wikimedia Foundation. Wikipedia offers articles on

Monday, June 9, 2025 – Definition and diagnostic criteria of clinical obesityRubino, Francesco et al.The Lancet Diabetes & Endocrinology, Volume 13, Issue 3, 221 – 262 The Lancet Diabetes & Endocrinology

Saturday, June 7, 2025 – Clinical trials are carefully designed research studies conducted in humans to evaluate the safety, efficacy, and overall benefit of medical interventions such as drugs, biologics,

Thursday, June 5, 2025 – Enforcement discretion means that a regulatory agency like the FDA (U.S. Food and Drug Administration) chooses not to enforce certain rules or regulations under specific

Thursday, June 5, 2025 – Abdul-Rahman T, Roy P, Ahmed FK, Mueller-Gomez JL, Sarkar S, Garg N, Femi-Lawal VO, Wireko AA, Thaalibi HI, Hashmi MU, Dzebu AS, Banimusa SB, Sood

Wednesday, June 4, 2025 – Chen H, Liu S, Gao S, Shi H, Yan Y, Xu Y, Fang J, Wang W, Chen H, Liu Z. Pharmacovigilance analysis of neurological adverse

Wednesday, June 4, 2025 – Drug delivery for incretins refers to how medications that mimic or enhance the activity of incretin hormones—primarily GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide)—are

Wednesday, June 4, 2025 – by William A Seeds MD (Author) ($36.00) In The Quantum Power of GLP-1 Peptides: Unlocking the Science that Leads to Lasting Weight Loss and Optimal Healthspan, Dr. William A.Seeds

Tuesday, June 3, 2025 – This academic article, “Nutritional priorities to support GLP‐1 therapy for obesity,” is a joint advisory from several prominent American health organizations. It examines the use of GLP-1 receptor

Monday, June 2, 2025 – PharmaVoice article discusses the Trump administration’s decision not to expand Medicare and Medicaid coverage for GLP-1 obesity drugs, despite their increasing use and the potential for

Sunday, June 1, 2025 – Schmidt, Laura A., and Luc L. Hagenaars. “The Ozempic Era Could Shift Blame for Obesity From Individuals to Commercial Food Systems.” Issues in Science and Technology 41,

Saturday, May 31, 2025 – Vocabulary-GWAS – A Genome-Wide Association Study – a research method used to identify genetic variations (like single nucleotide polymorphisms or SNPs) associated with a specific

Friday, May 30, 2025 – This meta-analysis examines the impact of Glucagon-Like Peptide 1 Receptor Agonists (GLP1-RAs), medications used for obesity and diabetes, on the mental health and quality of

Thursday, May 29, 2025 – May 23, 2025Stat + by Katie Palmer https://ro.co/ https://lifemd.com/ Stat + reports on the evolving landscape of GLP-1 drug marketing, noting a shift in the

Wednesday, May 28, 2025 – This research paper explores the impact of amino acid restriction on weight loss, focusing on the unique effects of cysteine deficiency. The study demonstrates that cysteine restriction in mice, particularly those with compromised

Tuesday, May 27, 2025 – This abstract evaluates a multi-cancer early detection (MCED) blood test specifically designed for individuals with obesity, a group at higher risk for several cancers often without standard screening.

Tuesday, May 27, 2025 – What You Should Know:  – Mochi Health, a physician-guided obesity care program, announced the launch of its new insurance-based plans.  – These expanded offerings are

Tuesday, May 27, 2025 – The sources discuss Fractyl Health’s Rejuva GLP-1 gene therapy platform, highlighting preclinical data presented at ASGCT 2025 for its candidate RJVA-001. This research indicates that a single dose

Monday, May 26, 2025 – ChatGPTMay 26, 2025 Fatigue or low energy is a commonly reported side effect among users of GLP-1 receptor agonists like semaglutide (Ozempic/Wegovy) or tirzepatide (Mounjaro/Zepbound),

Sunday, May 25, 2025 – WSJ article discusses the growing trend of microdosing GLP-1 medications, like Ozempic and Zepbound, which are primarily used for weight loss and diabetes management. Some individuals

Saturday, May 24, 2025 – This scientific article examines the connection between aging and metabolic changes in humans. It focuses on age-related alterations in adipose tissue, muscle, and liver, noting how sedentary habits worsen these

Friday, May 23, 2025 – Glucagon-like peptide-1 receptor agonists compared with bariatric metabolic surgery and the risk of obesity-related cancer: an observational, retrospective cohort studyWolff Sagy, Yael et al. eClinicalMedicine,

Thursday, May 22, 2025 – There is a significant burden of chronic diseases in the United States, comparing its rates to other developed nations. One source from the Peterson-KFF Health System Tracker

Monday, May 19, 2025 – This systematic review and meta-analysis investigated the rate of weight regain after people stopped using GLP-1 receptor agonists (GLP-1 RAs) for weight management. The researchers identified relevant studies and analyzed the weight loss achieved

Saturday, May 17, 2025 – Global burden and strength of evidence for 88 risk factors in204 countries and 811 subnational locations, 1990–2021 : a systematic analysis for the Global Burden

Saturday, May 17, 2025 – ADVANCEMENTS IN GLP-1 ANALOG FORMULATION DEVELOPMENT: OVERCOMING CHALLENGES IN ORAL DELIVERYFebruary 14, 2025By Adare Pharmaceuticals Obesity is a significant global health challenge that requires lifestyle changes

Friday, May 16, 2025 – This talk at the discuss the development of new medications designed to address muscle loss that can occur alongside weight loss achieved with GLP-1 receptor agonists like semaglutide and tirzepatide. While